Ulrich T. Hacker - Publications

Personalized systemic treatment of metastatic esophageal cancer

Journal: Chirurgie (Heidelberg, Germany)

Published: July 23, 2026

UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA).

Journal: ESMO gastrointestinal oncology

Published: April 30, 2026

FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: April 03, 2026

Adeno-Associated Virus Vectors-a Target of Cellular and Humoral Immunity-are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies.

Journal: Human gene therapy

Published: August 28, 2024

Exceptional Response of BRAFV600E-Mutated Acinar Cell CUP to BRAF/MEK Inhibition.

Journal: JCO precision oncology

Published: May 31, 2024

SAGA-a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma.

Journal: ESMO gastrointestinal oncology

Published: April 12, 2024

Immunotherapy for gastrointestinal cancer

Journal: Deutsche medizinische Wochenschrift (1946)

Published: April 02, 2024

SAPHIR: real-world clinical research platform for molecular testing, treatment, and clinical and patient-reported outcomes in patients with gastroesophageal cancer in Germany.

Journal: ESMO real world data and digital oncology

Published: December 19, 2023

Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: a multicenter, prospective study (EBV PRESAGE study).

Journal: Frontiers in oncology

Published: August 11, 2023

Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 25, 2023

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.

Journal: Nature communications

Published: April 05, 2023

On the way to developing AAV-based vaccines as novel tools for cancer immunotherapy.

Journal: Molecular therapy. Methods & clinical development

Published: March 06, 2023